In a small sign of a possible improvement in the sluggish biotech initial public offering (IPO) market, Apogee Therapeutics has said it expects gross proceeds of $300 mill
Biotech watchers lamenting a fall-off in public listings for biotech companies will take some heart from Acelyrin’s upsized initial public offering, which ended up at the
Johnson & Johnson’s consumer health unit Kenvue looks set to raise $3.8 billion in an upsized initial public offering (IPO), valuing the business at around $41 billion
Initial public offerings in the biotech sector nosedived last year after a lot of activity in 2021, but have remained few and far between this year amid tough economic con
Exscientia's artificial intelligence-based drug discovery engine is still largely unproven, but that hasn't stopped the company raking in funding from investors keen to back its platform.
Shares in DNA sequencing specialist Oxford Nanopore rocketed after the company made its debut on the London Stock Exchange yesterday, rising nearly 50% to propel its valuation up towards th
Eisai and Biogen have their second regulatory approval for anti-amyloid therapy Leqembi – in Japan – as a treatment for slowing the progression of Alzheimer’s disease.
Drug discovery is usually a goal-driven and iterative process, as researchers look for innovative new routes to target particular diseases and study those diseases in afflicted patients to learn ho